A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
BACKGROUND: The COVID-19 pandemic has imposed an enormous burden on health care systems around the world. In the past, the administration of convalescent plasma of patients having recovered from SARS and severe influenza to patients actively having the disease showed promising effects on mortality and appeared safe. Whether or not this also holds true for the novel SARS-CoV-2 virus is currently unknown. METHODS: DAWn-Plasma is a multicentre nation-wide, randomized, open-label, phase II proof-of-concept clinical trial, evaluating the clinical efficacy and safety of the addition of convalescent... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2020 |
Verlag/Hrsg.: |
BioMed Central
|
Schlagwörter: | Adult / Antibodies / Viral / Belgium / COVID-19 / Combined Modality Therapy / Female / Global Burden of Disease / Hospitalization / Humans / Immunization / Passive / Male / Mortality / Respiration / Artificial / SARS-CoV-2 / Safety / Standard of Care / Treatment Outcome / Convalescent plasma / Immunity |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26980227 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/253877 |